| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 12,6 k € | +403.9% | 2,5 k € | +118.9% | -13,2 k € | -142.6% | 31,0 k € | +189.1% | -34,8 k € | -161.6% | 56,5 k € | -78.8% | 267,0 k € | +6076.8% | -4,5 k € | -939.2% | 532,3 € | -94.4% | 9,4 k € | +334.1% | 2,2 k € | +148.7% | -4,5 k € | +6.5% | -4,8 k € | -30.1% | -3,7 k € | -2.7% | -3,6 k € | -0.1% | -3,6 k € | -3.4% | -3,5 k € | -2.7% | -3,4 k € | +62.2% | -8,9 k € | |
| EBITDA | 12,6 k € | +403.9% | 2,5 k € | +118.9% | -13,2 k € | -142.6% | 31,0 k € | +189.1% | -34,8 k € | -161.6% | 56,5 k € | -78.8% | 267,0 k € | +6076.8% | -4,5 k € | -939.2% | 532,3 € | -94.4% | 9,4 k € | +334.1% | 2,2 k € | +148.7% | -4,5 k € | +12.8% | -5,1 k € | -27.6% | -4,0 k € | -2.5% | -3,9 k € | -0.1% | -3,9 k € | -3.0% | -3,8 k € | -11.4% | -3,4 k € | +64.5% | -9,6 k € | |
| Operating profit | 12,6 k € | +403.9% | 2,5 k € | +118.9% | -13,2 k € | -142.6% | 31,0 k € | +189.1% | -34,8 k € | -161.6% | 56,5 k € | -78.8% | 267,0 k € | +6076.8% | -4,5 k € | -939.2% | 532,3 € | -94.4% | 9,4 k € | +334.1% | 2,2 k € | +148.7% | -4,5 k € | +12.8% | -5,1 k € | -27.6% | -4,0 k € | -2.5% | -3,9 k € | -0.1% | -3,9 k € | -3.0% | -3,8 k € | -11.4% | -3,4 k € | +64.5% | -9,6 k € | |
| Profit/loss | 11,1 k € | +539.1% | -2,5 k € | +85.4% | -17,2 k € | -142.6% | 40,4 k € | +179.7% | -50,7 k € | -271.0% | 29,7 k € | -84.3% | 188,7 k € | +5148.7% | -3,7 k € | +68.6% | -11,9 k € | -240.7% | 8,4 k € | +811.9% | -1,2 k € | +77.7% | -5,3 k € | -3.8% | -5,1 k € | -7.8% | -4,8 k € | -7.9% | -4,4 k € | +9.9% | -4,9 k € | +14.8% | -5,7 k € | -10.4% | -5,2 k € | +52.9% | -11,0 k € | |
| Equity | 168,8 k € | +7.0% | 157,7 k € | -1.6% | 160,3 k € | -9.7% | 177,5 k € | +29.5% | 137,1 k € | -27.0% | 187,8 k € | +18.8% | 158,1 k € | +617.0% | -30,6 k € | -13.9% | -26,8 k € | -79.5% | -15,0 k € | +36.1% | -23,4 k € | -5.3% | -22,2 k € | -31.5% | -16,9 k € | -43.6% | -11,8 k € | -67.9% | -7,0 k € | -170.1% | -2,6 k € | -212.5% | 2,3 k € | -71.4% | 8,1 k € | -39.3% | 13,3 k € | |
| Total assets | 1,7 M € | +39.5% | 1,2 M € | +33.2% | 931,7 k € | +19.9% | 777,0 k € | -63.1% | 2,1 M € | -29.1% | 3,0 M € | +26.1% | 2,4 M € | -25.5% | 3,2 M € | +13.6% | 2,8 M € | +95.5% | 1,4 M € | +23.7% | 1,2 M € | +16177474.6% | 7,1 € | 0.0% | 7,1 € | -100.0% | 18,7 k € | -16.1% | 22,2 k € | -12.9% | 25,5 k € | -56.0% | 58,0 k € | +0.2% | 57,9 k € | +0.1% | 57,8 k € | |
| Cash | 38,1 k € | +78.6% | 21,4 k € | -73.4% | 80,2 k € | +10.5% | 72,6 k € | +30.4% | 55,7 k € | -44.9% | 101,0 k € | +2386.8% | 4,1 k € | +192.0% | 1,4 k € | +784.2% | 157,3 € | -85.8% | 1,1 k € | — | — | — | — | — | — | 48,4 k € | +0.2% | 48,3 k € | +0.2% | 48,3 k € | ||||||||
| Debts | 1,6 M € | +44.2% | 1,1 M € | +40.4% | 770,3 k € | +28.5% | 599,5 k € | -69.3% | 2,0 M € | -29.3% | 2,8 M € | +25.6% | 2,2 M € | -31.1% | 3,2 M € | +13.6% | 2,8 M € | +95.8% | 1,4 M € | +22.3% | 1,2 M € | +5178.2% | 22,2 k € | +32.7% | 16,7 k € | -44.7% | 30,3 k € | +4.0% | 29,1 k € | +4.0% | 28,0 k € | -49.6% | 55,6 k € | +11.7% | 49,7 k € | +11.9% | 44,4 k € | |
Public limited company · Sint-Martens-Latem · incorporated on 19/02/1985
Public limited company profitable and well capitalised. Cash position rising (+78.6%).
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
Eurodrug Laboratories is a Public limited company incorporated in 1985. Its registered office is in Sint-Martens-Latem.
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette